Clinical Trial Update: Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD [Phase 3]

View source ↗

Summary

A randomized, double-blind, placebo-controlled Phase 3 trial of REL-1017 as an adjunctive treatment for Major Depressive Disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Major Depressive Disorder

Drugs mentioned

• REL-1017

Snippet

Sponsor: Levomecor Inc. | Conditions: Major Depressive Disorder, Depression | Phase 3 | Status: TERMINATED